Efficacy of DNA vaccines forming E7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers

Human Gene Therapy

Volumn 24, Issue 5, 2013, Pages 533-544

  Lescaille, Geraldine ^a,b   Pitoiset, Fabien ^a,b   MacEdo, Rodney ^a,b   Baillou, Claude ^a,b   Huret, Christophe ^a   Klatzmann, David ^a,b,c   Tartour, Eric ^d   Lemoine, François M ^a,b,c   Bellier, Bertrand ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; E7 SPECIFIC PLASMO RETRO VIRUS LIKE PARTICLE VACCINE; IMIQUIMOD; PLASMID DNA; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NEOPLASM; NONHUMAN; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS;

ANIMALS; CAPSID PROTEINS; CELL LINE, TUMOR; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84877851608     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.037     Document Type: Article

References (49)

1. Agnandji, S.T., Lell, B., Soulanoudjingar, S.S., et al. (2011). First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863-1875.
2. Allen, C.T., Judd, N.P., Bui, J.D., and Uppaluri, R. (2012). The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122, 144-157.
3. Baban, B., Chandler, P.R., Sharma, M.D., et al. (2009). IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183, 2475-2483.
4. Bachmann, M.F., and Jennings, G.T. (2010). Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787-796.
5. Badoual, C., Sandoval, F., Pere, H., et al. (2010). Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 32, 946-958.
6. Bellier, B., Dalba, C., Clerc, B., et al. (2006). DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24, 2643-2655.
7. Bellier, B., Huret, C., Miyalou, M., et al. (2009). DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 27, 5772-5780.
8. Berraondo, P., Nouze, C., Preville, X., et al. (2007). Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res. 67, 8847-8855.
9. + T cell immune responses compared with intramuscular injection and intradermal gene gun delivery. Vaccine 27, 5450-5459.
10. Buonaguro, L., Tagliamonte, M., Tornesello, M.L., and Buona-guro, F.M. (2011). Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines 10, 1569-1583.
11. Chackerian, B. (2007). Virus-like particles: Flexible platforms for vaccine development. Expert Rev. Vaccines 6, 381-390.
12. Chaput, N., Conforti, R., Viaud, S., et al. (2008). The Janus face of dendritic cells in cancer. Oncogene 27, 5920-5931.
13. Chaturvedi, A.K., Engels, E.A., Pfeiffer, R.M., et al. (2011). Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29, 4294-4301.
14. Chuang, C.M., Monie, A., Hung, C.F., and Wu, T.C. (2010). Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J. Biomed. Sci. 17, 32.
15. Daemen, T., Riezebos-Brilman, A., Regts, J., et al. (2004). Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: Effects of the route of immunization. Antivir Ther. 9, 733-742.
16. Dalba, C., Bellier, B., Kasahara, N., and Klatzmann, D. (2007). Replication-competent vectors and empty virus-like particles: New retroviral vector designs for cancer gene therapy or vaccines. Mol. Ther. 15, 457-466.
17. hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J. Clin. Invest. 119, 2648-2662.
18. de Vos van Steenwijk, P.J., Ramwadhdoebe, T.H., Lowik, M.J., et al. (2012). A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol. Immunother. 61, 1485-1492.
19. + T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395, 45-55.
20. Dupuy, F.P., Mouly, E., Mesel-Lemoine, M., et al. (2005). Lenti-viral transduction of human hematopoietic cells by HIV-1-and SIV-based vectors containing a bicistronic cassette driven by various internal promoters. J. Gene Med. 7, 1158-1171.
21. Galarza, J.M., Latham, T., and Cupo, A. (2005). Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18, 244-251.
22. Garrone, P., Fluckiger, A.C., Mangeot, P.E., et al. (2011). A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3, 94ra71.
23. Georgel, P., Jiang, Z., Kunz, S., et al. (2007). Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362, 304-313.
24. Gillison, M.L., Koch, W.M., Capone, R.B., et al. (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92, 709-720.
25. Gomez-Gutierrez, J.G., Elpek, K.G., Montes De Oca-Luna, R., et al. (2007). Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol. Immunother. 56, 997-1007.
26. Greenstone, H.L., Nieland, J.D., de Visser, K.E., et al. (1998). Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. U.S.A. 95, 1800-1805.
27. Jennings, G.T., and Bachmann, M.F. (2008). The coming of age of virus-like particle vaccines. Biol. Chem. 389, 521-536.
28. Kenter, G.G., Welters, M.J., Valentijn, A.R., et al. (2008). Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14, 169-177.
29. Kenter, G.G., Welters, M.J., Valentijn, A.R., et al. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847.
30. Kreimer, A.R., Clifford, G.M., Boyle, P., and Franceschi, S. (2005). Human papillomavirus types in head and neck squa-mous cell carcinomas worldwide: A systematic review. Cancer Epidemiol. Biomarkers Prev. 14, 467-475.
31. Link, A., Zabel, F., Schnetzler, Y., et al. (2012). Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J. Immunol. 188, 3724-3733.
32. Mansilla, C., Berraondo, P., Durantez, M., et al. (2012). Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int. J. Cancer 131, 641-651.
33. Marsac, D., Loirat, D., Petit, C., et al. (2002). Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J. Virol. 76, 7544-7553.
34. Marur, S., D'Souza, G., Westra, W.H., and Forastiere, A.A. (2010). HPV-associated head and neck cancer: A virus-related cancer epidemic. Lancet Oncol. 11, 781-789.
35. Monie, A., Tsen, S.W., Hung, C.F., and Wu, T.C. (2009). Therapeutic HPV DNA vaccines. Expert Rev. Vaccines 8, 1221-1235.
36. Nasman, A., Attner, P., Hammarstedt, L., et al. (2009). Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int. J. Cancer 125, 362-366.
37. Ohlschlager, P., Spies, E., Alvarez, G., et al. (2011). The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int. J. Cancer 128, 473-481.
38. Pages, F., and Kroemer, G. (2011). Prognostic impact of anticancer immune responses: An introduction. Semin. Im-munopathol. 33, 317-319.
39. Re, F., and Strominger, J.L. (2001). Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 276, 37692-37699.
40. Riezebos-Brilman, A., Regts, J., Freyschmidt, E.J., et al. (2005). Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther. 12, 1410-1414.
41. Su, J.H., Wu, A., Scotney, E., et al. (2010). Immunotherapy for cervical cancer: Research status and clinical potential. Bio-Drugs 24, 109-129.
42. Temchura, V.V., Tenbusch, M., Nchinda, G., et al. (2008). Enhancement of immunostimulatory properties of exosomal vaccines by incorporation of fusion-competent G protein of vesicular stomatitis virus. Vaccine 26, 3662-3672.
43. + cervical intraepithelial neoplasia 2/3. Clin. Cancer Res. 15, 361-367.
44. Vingert, B., Adotevi, O., Patin, D., et al. (2006). The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur. J. Immunol. 36, 1124-1135.
45. Welters, M.J., Kenter, G.G., de Vos van Steenwijk, P.J., et al. (2010). Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 107, 11895-11899.
46. Wingender, G., Garbi, N., Schumak, B., et al. (2006). Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12-20.
47. Wu, A., Zeng, Q., Kang, T.H., et al. (2011). Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther. 18, 304-312.
48. Xiang, S.D., Scalzo-Inguanti, K., Minigo, G., et al. (2008). Promising particle-based vaccines in cancer therapy. Expert Rev. Vaccines 7, 1103-1119.
49. Zwaveling, S., Ferreira Mota, S.C., Nouta, J., et al. (2002). Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358.